Orion Pharma Limited

ORIONPHARM

BD0486OPL004

Pharmaceuticals

End-of-day quote Dhaka S.E. Other stock markets 06:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
62.8 ^BDT	-2.94%		-4.41%	-21.11%

Feb. 04	Orion Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	CI
2023	Orion Pharma Limited Reports Earnings Results for the First Quarter Ended September 30, 2023	CI

Orion Pharma Limited Recommends Cash Dividend for the Year Ended on June 30, 2019

November 07, 2019 at 10:17 am EST

Orion Pharma Limited of The Board of Directors has recommended 15% cash dividend for the year ended on June 30, 2019.

Latest news about Orion Pharma Limited

Orion Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 04	CI
Orion Pharma Limited Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 15	CI
Orion Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-02	CI
Orion Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-12	CI
Orion Pharma Limited Reports Earnings Results for the First Quarter Ended September 30, 2022	22-11-19	CI
Orion Pharma Limited Recommends Cash Dividend for the Year Ended June 30, 2022	22-11-14	CI
Orion Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022	22-04-26	CI
Orion Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021	22-01-29	CI
Orion Pharma Limited Reports Earnings Results for the First Quarter Ended September 30, 2021	21-11-14	CI
Orion Pharma Limited Reports Earnings Results for the Second Quarter Ended December 31, 2020	21-02-01	CI
Orion Pharma Limited Recommends Cash Divided for the Year Ended on June 30, 2020	20-11-09	CI
Orion Pharma Limited Reports Earnings Results for the Third Quarter Ended March 31, 2020	20-05-19	CI
Orion Pharma Limited Appoints Zareen Karim as Managing Director	20-01-09	CI
Orion Pharma Limited Reports Earnings Results for the First Quarter Ended September 30, 2019	19-11-12	CI
Orion Pharma Limited Recommends Cash Dividend for the Year Ended on June 30, 2019	19-11-07	CI
Orion Pharma Limited Reports Earnings Results for the Third Quarter Ended March 31, 2019	19-05-06	CI
Orion Pharma Limited Reports Earnings Results for the Second Quarter Ended December 31, 2018	19-02-04	CI
Orion Pharma Limited Reports Earnings Results for the First Quarter Ended September 30, 2018	18-11-14	CI
Orion Pharma Limited Recommends Cash Dividend for the Year Ended on June 30, 2018	18-11-01	CI
Orion Pharma Limited Reports Unaudited Consolidated Earnings Results for Third Quarter and Nine Months Ended March 31, 2018	18-04-29	CI
Orion Pharma Limited Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended December 31, 2017	18-01-29	CI
Orion Pharma Limited Announces Consolidated Unaudited Earnings Results for the First Quarter Ended September 30, 2017	17-11-14	CI
Orion Pharma Limited Reports Consolidated Earnings Results for the Year Ended on June 30, 2017	17-11-07	CI
Orion Pharma Limited Announces Consolidated Unaudited Earnings Results for the Third Quarter and Nine Months Ended March 2017	17-05-01	CI
Orion Pharma Signs $34 Million Loan Deal with BHF-Bank of Germany to Expand its Facilities	17-02-27	CI

Orion Pharma Limited is a Bangladesh-based pharmaceutical company. The Company is engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health- related consumer products. The Company's products include Ambronil, Angimet MR, Arovent, Axet, Avison, Azalid, Angimet, Alve, Anvert, Baclon, Betacal, Bisoloc, Bonec, Broket, Bromazep, Boncare, Sefin, Stimulin, Silvage, ROVEX, Rupenta, Rispa, Riz, Rivo, Procap, Pep Plus, Pep, Pedicon, Pedicef, Oranex Capsule, Orsal Syrup, Orsal, Ortac, Ormin, Orlev, Orioplex, Oriodox, Orfenac, Onium, Onasia, Oclazid, Novoxen, Novodol Tablet, Nidazyl, Nervex, NOVELTA, Nosedex, Noak, Newage, Neulyn, Nugesic, Losan-D, Losan D, Losan, Lopres, Lipex, GoldKid, Goldage, Glory, Ezylax Syrup, Eroflam, Exor, Eprel, ESP, Enliven, EC PLUS, EC, Deslor Plus, Deslor, Deconil, Cosy, Co-Axet, Cloramin Syrup, Cefditor, Conaz, Combivit, Clognil Plus, Clognil and CCB.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ORION PHARMA LIMITED	-21.11%	134M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B